JP2009501177A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009501177A5 JP2009501177A5 JP2008520794A JP2008520794A JP2009501177A5 JP 2009501177 A5 JP2009501177 A5 JP 2009501177A5 JP 2008520794 A JP2008520794 A JP 2008520794A JP 2008520794 A JP2008520794 A JP 2008520794A JP 2009501177 A5 JP2009501177 A5 JP 2009501177A5
- Authority
- JP
- Japan
- Prior art keywords
- patent application
- application publication
- international patent
- insulin
- lantus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940060975 lantus Drugs 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- -1 HMR1964 Chemical class 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 239000002582 adenosine A1 receptor agonist Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005033099A DE102005033099A1 (de) | 2005-07-15 | 2005-07-15 | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
| PCT/EP2006/006848 WO2007009655A1 (de) | 2005-07-15 | 2006-07-13 | 1,4-BENZOTHIAZEPIN-l, 1-DIOXIDDERIVAT, VERFAHREN ZU DESSEN HERSTELLUNG, DIESE VERBINDUNG ENTHALTENDE ARZNEIMITTEL UND DESSEN VERWENDUNG ALS HYPOLIPIDÄMIKUM |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009501177A JP2009501177A (ja) | 2009-01-15 |
| JP2009501177A5 true JP2009501177A5 (enExample) | 2009-09-03 |
Family
ID=36997833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008520794A Abandoned JP2009501177A (ja) | 2005-07-15 | 2006-07-13 | １，４−ベンゾチアゼピン１，１−ジオキシド誘導体、その製造方法、該化合物を含有する医薬、及び脂質低下薬としてのその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7615536B2 (enExample) |
| EP (1) | EP1912960A1 (enExample) |
| JP (1) | JP2009501177A (enExample) |
| KR (1) | KR20080031738A (enExample) |
| CN (1) | CN101223151A (enExample) |
| AU (1) | AU2006272042A1 (enExample) |
| BR (1) | BRPI0613462A2 (enExample) |
| CA (1) | CA2614524A1 (enExample) |
| DE (1) | DE102005033099A1 (enExample) |
| IL (1) | IL188608A0 (enExample) |
| MA (1) | MA29619B1 (enExample) |
| MX (1) | MX2008000426A (enExample) |
| NO (1) | NO20080789L (enExample) |
| NZ (1) | NZ565292A (enExample) |
| RU (1) | RU2008105756A (enExample) |
| TW (1) | TW200745069A (enExample) |
| UY (1) | UY29675A1 (enExample) |
| WO (1) | WO2007009655A1 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009509988A (ja) | 2005-09-29 | 2009-03-12 | サノフィ−アベンティス | フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用 |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| DE102006053636B4 (de) | 2006-11-14 | 2008-09-18 | Sanofi-Aventis Deutschland Gmbh | Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung |
| DE102006053637B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| JP2010509252A (ja) | 2006-11-14 | 2010-03-25 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 改善された特性を有する新規な１，４−ベンゾチエピン−１，１−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物、及びそれらの使用 |
| DE102006053635B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| PL3400944T3 (pl) | 2010-11-04 | 2020-11-16 | Albireo Ab | Inhibitory ibat w leczeniu chorób wątroby |
| PT2637646T (pt) | 2010-11-08 | 2016-08-17 | Albireo Ab | Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar |
| US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US20140323412A1 (en) | 2011-10-28 | 2014-10-30 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| SG10201909122QA (en) | 2011-10-28 | 2019-11-28 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| KR102560954B1 (ko) | 2014-06-25 | 2023-07-31 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| CN108601745B (zh) | 2016-02-09 | 2021-12-07 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| WO2019032027A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| EP3802504B1 (en) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| EP3810084A1 (en) | 2018-06-20 | 2021-04-28 | Albireo AB | Pharmaceutical formulation of odevixibat |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| WO2020033919A1 (en) | 2018-08-10 | 2020-02-13 | Diapin Therapeutics, Llc | Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders |
| DK3921028T3 (da) | 2019-02-06 | 2023-01-23 | Albireo Ab | Benzothiadiazepinforbindelser og anvendelse deraf som galdesyremodulatorer |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| CN118834175A (zh) | 2019-02-06 | 2024-10-25 | 阿尔比里奥公司 | 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| TWI877263B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| DK4069360T3 (da) | 2019-12-04 | 2024-02-26 | Albireo Ab | Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer |
| CN114761018B (zh) | 2019-12-04 | 2025-12-02 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| WO2021110886A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AR120674A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiazepina y su uso como ácido biliar |
| WO2021110884A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| PT4069360T (pt) | 2019-12-04 | 2024-03-06 | Albireo Ab | Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar |
| ES2972045T3 (es) | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| JP7696897B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CN116157389B (zh) | 2020-08-03 | 2026-02-10 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| WO2022117778A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| JP2025516153A (ja) | 2022-04-22 | 2025-05-27 | アルビレオ・アクチボラグ | Ａｓｂｔ阻害剤の皮下投与 |
| AU2023285002A1 (en) | 2022-06-09 | 2024-12-05 | Albireo Ab | Treating hepatitis |
| US20240067617A1 (en) | 2022-07-05 | 2024-02-29 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US20240207286A1 (en) | 2022-12-09 | 2024-06-27 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE441189B (sv) * | 1984-02-07 | 1985-09-16 | Boliden Ab | Forfarande for framstellning av metalliskt bly genom smeltreduktion |
| PT864582E (pt) * | 1997-03-14 | 2003-10-31 | Aventis Pharma Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
-
2005
- 2005-07-15 DE DE102005033099A patent/DE102005033099A1/de not_active Ceased
-
2006
- 2006-07-13 JP JP2008520794A patent/JP2009501177A/ja not_active Abandoned
- 2006-07-13 BR BRPI0613462-9A patent/BRPI0613462A2/pt not_active Application Discontinuation
- 2006-07-13 MX MX2008000426A patent/MX2008000426A/es not_active Application Discontinuation
- 2006-07-13 TW TW095125565A patent/TW200745069A/zh unknown
- 2006-07-13 WO PCT/EP2006/006848 patent/WO2007009655A1/de not_active Ceased
- 2006-07-13 CN CNA2006800258356A patent/CN101223151A/zh active Pending
- 2006-07-13 NZ NZ565292A patent/NZ565292A/en unknown
- 2006-07-13 RU RU2008105756/04A patent/RU2008105756A/ru not_active Application Discontinuation
- 2006-07-13 AU AU2006272042A patent/AU2006272042A1/en not_active Abandoned
- 2006-07-13 EP EP06776211A patent/EP1912960A1/de not_active Withdrawn
- 2006-07-13 KR KR1020087001183A patent/KR20080031738A/ko not_active Withdrawn
- 2006-07-13 CA CA002614524A patent/CA2614524A1/en not_active Abandoned
- 2006-07-14 UY UY29675A patent/UY29675A1/es unknown
-
2008
- 2008-01-06 IL IL188608A patent/IL188608A0/en unknown
- 2008-01-07 US US11/970,281 patent/US7615536B2/en not_active Expired - Fee Related
- 2008-01-08 MA MA30556A patent/MA29619B1/fr unknown
- 2008-02-13 NO NO20080789A patent/NO20080789L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009501177A5 (enExample) | ||
| JP2009501178A5 (enExample) | ||
| JP2008506632A5 (enExample) | ||
| JP2009514837A5 (enExample) | ||
| WO2007003962A3 (en) | Gpcr agonists | |
| CN1878757A (zh) | 吡啶酮衍生物及其应用 | |
| JP2007522220A5 (enExample) | ||
| WO2008062273A8 (en) | Solid oral dosage form having antidiabetic drug combination | |
| CL2012002521A1 (es) | Composicion farmaceutica que comprende un inhibidor de dpp iv seleccionado de un grupo definido, un primer diluyente, un segundo diluyente: manitol, un segundo diluyente: almidon pregelatinizado, un aglutinante y un lubricante; util en el tratamiento de diabetes. (divisional de la sol. 1260-07). | |
| WO2007107470A3 (en) | Pyrazoles as 11-beta-hsd-1 | |
| NO20072608L (no) | Biaryloksymetylarenkarboksylsyrer | |
| WO2005044192A3 (en) | Triazole compounds and uses related thereto | |
| WO2008006043A3 (en) | 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents | |
| CL2006003672A1 (es) | Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad. | |
| JP2006502187A5 (enExample) | ||
| EP1816122A3 (en) | 3,4,5-substituted piperidines as therapeutic compounds | |
| NO20075399L (no) | Benzimidazolerivat og anvendelse derav | |
| JP2007502817A5 (enExample) | ||
| JP2008513510A5 (enExample) | ||
| JP2005509503A5 (enExample) | ||
| JP2008506643A5 (ja) | 糖尿病の治療用の血糖値低下活性成分として使用するためのホスホチロシン・ホスファターゼ１ｂ(ｐｔｐ１ｂ)阻害剤としてのジフェニルアミン置換サリチルチアゾール誘導体及び関連化合物 | |
| DE502005010427D1 (de) | Physiologisch aktive zusammensetzung gegen diabetes | |
| JP2004532828A5 (enExample) | ||
| JP2005507880A5 (enExample) | ||
| JP2004505922A5 (enExample) |